UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
       PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
                                      1934

       Date of Report (Date of earliest event reported) November 30, 2009

                                 Hydromer, Inc.
                                 --------------
             (Exact name of registrant as specified in its chapter)

          New Jersey                0-10683                     22-2303576
          ----------                -------                     ----------
(State or other jurisdiction      (Commission                  (IRS Employer
      of incorporation)           File Number)               Identification No.)

35 Industrial Parkway

            Branchburg, N.J.                                         08876
            ----------------                                         -----
(Address of principal executive offices)                          (Zip Code)


Registrant's telephone number, including area code       (908) 722 - 5000




Check  the  appropriate  box  below  if  the  Form  8-K  filing  is  intended to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

(  )  Written communications pursuant to Rule 425 under the Securities Act
      (17 CFR 230.425)

(  )  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

(  )  Pre-commencement communications pursuant to Rule 14-2(b) under the
      Exchange Act (17 CFR240.14d-2(b))

(  )  Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR240-13e-4(c))

































Item 2.01. Completion of Acquisition or Disposition of Assets

Press  Release  Announcing  the  sales  of the Medical OEM Business to Forefront
Medical Technologies

                                 EXHIBIT INDEX

           Exhibit No.           Description of Exhibit
           -----------           ----------------------

           99.40                Press Release issued November 30, 2009



































































                                   SIGNATURES

Pursuant  to  the  requirements  of  the  Securities  Exchange  Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned hereunto duly authorized.

                                                        Hydromer, Inc.
                                                    _______________________
                                                        Registrant

                                                       /s/ Robert Y. Lee
                                                    _______________________
                                                         Robert Y. Lee
Date    December 1, 2009                           Chief Financial Officer
     _________________________































































         HYDROMER, INC. SELLS MEDICAL OEM BUSINESS TO FOREFRONT MEDICAL

BRANCHBURG, NJ--(November 30, 2009) - Hydromer, Inc. (OTCBB: HYDI) announces the
sale  of its Private Label Jejunostomy Catheter and Nasogastric Feeding Catheter
business  to Forefront Medical Technologies. Forefront Medical Technologies is a
wholly  owned  subsidiary of Vicplas International Limited, a company registered
in the Republic of Singapore.

Under  the  terms of this agreement Forefront Medical Technologies ("Forefront")
will  pay  US$800,000  in  cash  to  Hydromer,  Inc.'s  wholly  owned subsidiary
Biosearch  Medical  Products,  Inc. ("Biosearch"). $400,000 was payable upon the
effective date and the second $400,000 is held in escrow until the transition is
complete.  The  agreement  also  calls  for Biosearch to assign certain customer
supply agreements to Forefront and for a 3 year non-compete provision. Biosearch
will  continue  to manufacture these products during the transition at an agreed
upon  transfer  price.

In addition, a separate supply agreement has been entered between the two
parties for the Hydromer(R) hydrophilic coating solution used on those products.

"This  transaction was essential for our strategic realignment
allowing  us  to reclaim valuable medical clean room space for our higher margin
core business of medical coating services," commented Martin von Dyck, President
of  Biosearch  and  Executive  Vice  President  of  Hydromer,  Inc., adding, "In
addition  to  providing  us  with  an  enhanced  ability to focus on the medical
coatings  business  and  bolstering  our  balance  sheet,  we  are now in a much
stronger position to self finance our continued R&D and marketing efforts in our
diversified  product  portfolio  of  T-HEXX(R)  animal  hygiene,  Cosmetics  and
Industrial  coating  technologies."

Hydromer,  Inc.  is  a  technology-based  company  involved  in the research and
development,  manufacture  and  commercialization  of  specialized  polymer  and
hydrogel  products  for medical device, pharmaceutical, animal health, cosmetic,
personal  care,  and industrial uses. For the latest information about Hydromer,
Inc. and its products, please visit our web site at http://www.hydromer.com. For
additional  information please contact: Martin von Dyck, 908-722-5000, Executive
Vice President.

For additional information please contact:

Martin von Dyck
Executive Vice President
908-722-5000